Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2011) 26 P198

ECE2011 Poster Presentations Pituitary (111 abstracts)

Effects on metabolic parameters after 12-month treatment with a new once-a-week sustained release recombinant growth hormone (LB03002) in adult patients with GH deficiency (GHD)

J Roemmler , A Gockel , B Otto , M Bidlingmaier & J Schopohl


Medizinische Klinik Innenstadt, Munich, Germany.


Introduction: GH substitution in GH deficiency (GHD) must be subcutaneously administered daily. Recently, a new sustained release formulation of GH (LB03002) has been developed which has to be injected only once per week. As a sub-study to the double-blind, randomized, placebo-controlled, multicenter, phase-III-study we performed this prospective study to evaluate influences of the new GH formulation on metabolic parameters and the hormones leptin and ghrelin in adult patients with GHD.

Methods: Eleven patients with GHD (4f/7m, median age 58 years (29–69 years)) without any GH therapy for at least 6 months were included in the study. Eight patients were treated with LB03002 for 12 months, three patients started with placebo for 6 months and were then switched to LB03002 for another 6 months. A 3 h oral glucose tolerance test (OGTT) was performed at study entry and at study end. Additionally, IGF1, lipid parameters including cholesterol, LDL, HDL, and triglycerides, leptin, ghrelin, HbA1c and C-peptide were measured. Body composition was evaluated by dual-energy-X-ray-absorptiometry, waist/hip (WHR) and waist/height (WHtR) ratio by tape.

Results: Multiple of upper limit of normal (xULN) of IGF1 (0.23 (0.09–0.4) vs 0.71 (0.4–1.04), P<0.01), WHR (0.98 (0.86–1.04) vs 1.01 (0.86–1.05), P<0.05) and ghrelin levels (119.8 ng/l (67.7–266.6) vs 137 ng/l (67–289.5), P<0.05) were significantly higher and fat mass (34.7% (20.4–49.2) vs 32.4% (16.7–48.5), P<0.05) and leptin levels (11.2 μg/l (3.3–55.7) vs (7.05 μg/l (2.4–54.3), P<0.05) were significantly lower at study end. Glucose and insulin levels during OGTT as well as insulin resistance (HOMA-IR), insulin sensitivity (ISI), β-cell function (HOMA-β), C-peptide and HbA1c were not statistically significantly different before and after GH substitution, neither were BMI, WHtR, bone-mineral-density (BMD) and lipid parameters.

Conclusion: Substitution with LB03002 showed statistically significant reduction of fat mass, which leads to reduced leptin levels and increased ghrelin levels but does not seem to influence glucose and lipid metabolism.